相关实验视频
Updated: May 27, 2025

04:16
Electrocardiogram Recordings in Anesthetized Mice using Lead II
Published on: June 20, 2020
12.6K
管理长QT综合征患者,和常识
Peter J Schwartz1, Federica Dagradi1, Fulvio L F Giovenzana1
1Center for Cardiac Arrhythmias of Genetic Origin, Istituto Auxologico Italiano IRCCS, Via Pier Lombardo 22, 20135 Milan, Italy.
概括
对长QT综合征 (LQTS) 患者的动态风险评估方法,重点是每年评估和治疗优化,显著减少可植入心脏转换器除器 (ICD) 使用和不良事件,挑战当前的指南.
科学领域:
- 心脏病学 心脏病学
- 遗传学 遗传学 是一个
- 临床管理 临床管理
背景情况:
- 2022年欧洲指导方针有争议地建议在无症状,高风险的长 QT 综合征 (LQTS) 患者身上植入心脏转换器除器 (ICD).
- 之前提出的M-FACT风险评分旨在识别患有适当ICD休克高风险的患者.
研究的目的:
- 评估严格应用M-FACT评分和动态风险评估策略对LQTS患者的影响.
- 重新评估当前指南对高风险无症状LQTS患者的ICD植入的建议.
主要方法:
- 这是一项对近1000名基因型LQTS患者的回顾性研究.
- 每年重新评估心律失常风险,使用心电图,霍尔特监测和运动压力测试.
- 基于年度评估,优化治疗,包括β-阻断剂,左心交感肌,美克西莱丁或ICD植入物.
主要成果:
- 通过每年重新评估风险和优化治疗的动态方法,研究队列中死亡人数为零,事件很少.
- 在被评分认定为高风险的142名患者中,只有22人接受了ICD,只有3人经历了ICD冲击.
- 这与指南建议在高风险LQTS患者中更广泛考虑ICD的建议形成鲜明对比.
结论:
- 动态的,个性化的风险评估和治疗优化策略在管理LQTS患者中是有效的.
- 这些发现表明,需要重新考虑2022年欧洲指导方针对高风险无症状LQTS患者的ICD植入的建议.
- 每年重新评估和量身定制的干预措施可以减少不必要的ICD植入,同时保持患者的安全.
相关概念视频
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
888
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
888
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.2K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.2K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
761
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
761
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
702
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
702
Heart Failure Drugs: Inotropic Agents
499
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
499
Disturbances in Heart Rhythm
866
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
866

